6月29日，晶泰控股盘中上涨6.07%，报7.22港元，成交额2.16亿港元。
消息面上，公司近期利好密集释放：此前宣布与国际知名药企达成超4亿美元AI药物发现战略合作，聚焦GPCR靶点口服小分子疗法开发；同时启动1亿美元股份回购计划，自6月10日起实施。此外，国家系统性部署数据赋能AI发展，市场对公司物理AI基建价值重估预期升温。当日生命科学板块整体走强，康龙化成涨4.86%，药明生物涨4.18%，药明康德涨3.37%，板块共振进一步助推股价表现。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.